Higher expenses is inevitable due to further development of its ecommerce and fintech business segment. Perhaps we will see a higher profit margin on its next quarter based on its MOU with Tencent and Advwhere.

QR is releasing this week, shouldn't ppl have confidence in this coming quarter given the company prospect and its fundamentals are quite good based on the past 2 quarters? Also, RSI now showing an oversold signal, I guess disposal mainly from fund managers. So should we not priced in now?

No one pick up at this price given solid fundamentals?

I guess the proposal of 4-1 shares consolidation by the company is to gain larger shareholders, say institutional investor's confidence because most of the big players wouldn't want to invest in penny stocks with price below a certain price, say RM 0.30, also note that market value will remain unchanged after consolidation. On a side note, the proposal of diversifying their business into duty and tax free shop could theoretically boost the firm's future net earnings by 25%. By combining these 2 proposals, bigger players would want to join the game by chipping in big money and negative emotions of small investors may be elicited. As for now, I think people are worrying about the uncertainty of the stock's price after consolidation and therefore selling down pressure could be strong. If you were to ask me, I personally opine that the selling pressure is just a temporary retracement and once the consolidation is done, big fish will perhaps join the game due to brighter business prospect and stock price could possibly adjusted to higher level, hopefully twofold. Another rationale behind the consolidation could be HWGB wants to limit penny investors to goreng their stocks rather, they want reduce to reduce overall liquidity and attract big fishes to goreng it and boost their stock's price. All of these are just my personal assumptions, you guys don't have to take it too personally/seriously :)

If the proposal really comes into effect, it will contributes a guarantee amount of at least RM306,180 (based on BCM’s 51.03% equity interest in Cypress after the Proposed Subscription), around 8% of total net earnings based on 2016 figure. Future earnings are expected to improve since cost of sales for its medical devices segments are falling from 2015 to 2016 and is presumed to remain steady for the upcoming years. I personally think that such subscription will help the company to boost its product varieties and therefore gain more customer base and also market shares. Hence, this stock shouldn't be stop at the price of 0.18 but instead, higher level of at least 0.20++.